## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.8% below STRENGTH zone (3.0-6.0%); PEG 1.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($659.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma**
- Source: Quiver Quantitative | 20251207T220841 | Somewhat-Bullish | Relevance: 100%
-  Regeneron Pharmaceuticals announced promising interim results from its Phase 1/2 LINKER-MM4 trial for Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma. The trial showed that all dose groups achieved a very good partial response or better (VGPR+) of ≥70%, with a high rate of minimal residual disease negative status. Regeneron will host a virtual investor event on December 10, 2025, to discuss its multiple myeloma development program further, highlighting the drug's potential as a foundational component for frontline treatment.

**2. Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi**
- Source: MarketBeat | 20251206T081310 | Somewhat-Bullish | Relevance: 100%
-  Amundi significantly reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% in Q2 2025, selling 706,770 shares, though it still holds 897,131 shares valued at $491.4 million. Despite insider selling, other institutional investors like Marshall Wace and Dodge & Cox increased their positions, with institutional ownership nearing 83.31%. Regeneron reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, and maintains a "Moderate Buy" consensus with an average target price of $777.36.

**3. Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251208T130838 | Somewhat-Bullish | Relevance: 99%
- Natixis increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 4.0% in the second quarter, acquiring an additional 2,751 shares to hold a total of 72,180 shares valued at approximately $37.9 million. Other institutional investors like Bank of Nova Scotia, Federated Hermes Inc., and Marshall Wace LLP also significantly boosted their holdings. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating with an average target price of $777.36.

**4. Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251207T120923 | Bullish | Relevance: 99%
-  Federated Hermes Inc. significantly increased its stake in Regeneron Pharmaceuticals ($REGN) by 491.2% in Q2, acquiring an additional 204,045 shares and bringing its total holdings to 245,587 shares valued at $128.93 million. This comes as other major institutions have also built substantial positions, leading to institutional investors owning 83.31% of the company. Regeneron recently surpassed EPS estimates and announced a quarterly dividend, while analysts maintain a "Moderate Buy" rating with a consensus target price of $777.36.

**5. Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree**
- Source: Trefis | 20251209T045343 | Neutral | Relevance: 98%
-  Regeneron Pharmaceuticals (REGN) stock has experienced an 11% decline over an 8-day losing streak. The article headline indicates a significant recent drop in the company's stock value, suggesting a period of negative market performance for the pharmaceutical giant.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |
| 2025-11-24 | Scotiabank | $770 | $650 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |
| 2025-11-24 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $11M sold (5 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +18%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +18%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.5B |
| Beta | 0.37 |
| 52W Range | $476.49 - $800.99 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 17.8 |
| Current P/E | 16.3 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -3.8% to -6.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.8pp (needs >3.0% for momentum thesis). Underperforming sector by 3.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-9.16), momentum weakening. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.82% (CS: 2) | Weak |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | -9.16 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $703.26
- **Stop Loss:** $659.80 (6.2% risk)
- **Target:** $746.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 11
- **Position Value:** $7,735.86
- **Portfolio %:** 7.74%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*